LOW DOSE NALTREXONE RESEARCHCURRENT MEDICAL RESEARCH IN PEER-REVIEWED JOURNALS
Humaira Khan, MBBS, MCPS, MHSc, Medicor Epidemiologist and CEO
and Akbar Khan, MD, Medicor Medical Director
A sample of the current research on LDN (and OGF) is provided here. The research demonstrates the role of LDN in controlling harmful inflammation in the body, and also shows a more direct role against cancer.
Full text articles are available by clicking the medical journal titles. In some cases the articles are not freely available online. For those, only the abstracts are provided.
Proper use of LDN requires assistance from your family doctor or naturopathic doctor, for monitoring and dose adjustment advice.Akbar Khan, MD
“Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo”.
“Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone.”
Endogenous Opioid Inhibition of Proliferation of T and B Cell Subpopulations in Response to Immunization for Experimental Autoimmune Encephalomyelitis
“OGF or LDN repress proliferation of CD4+ and CD8+T cells and B220+ B lymphocytes in the spleen and lymph nodes of immunized mice within a week of immunization.”
“These data provide novel mechanistic pathways underlying the efficacy of OGF and LDN therapy for MS.”
Long-Term Remission of Adenoid Cystic Tongue Carcinoma with Low Dose Naltrexone and Vitamin D3 – A Case Report
“At the time of this writing, the patient has been re-assessed by the otolaryngologist who confirmed he remains without clinical evidence of cancer. He has remained asymptomatic on therapy, and is just approaching the four year mark (47 months so far).”
“There were no complications from the LDN or high dose vitamin D, and no conventional therapy was ever introduced.”
Safety and Tolerability of Low Dose Naltrexone Therapy in Children with Moderate to Severe Crohn's Disease: A Pilot Study
“Oral naltrexone was well tolerated without any serious adverse events in children with moderate to severe Crohn’s disease.”
“Twenty five percent of those treated with naltrexone were considered in remission…and 67% had improved with mild disease activity…at the end of the study. Systemic and social quality of life improved with naltrexone treatment (p=0.035).”
“We believe that by the mechanisms presented herein, LDN demonstrates significant potential to increase disease-free as well as overall survival in people with FL [follicular lymphoma].”
“Accumulating evidence suggests that LDN can promote health supporting immune-modulation which may reduce various oncogenic and inflammatory autoimmune processes.”
“…it may also have a role in promoting stress resilience, exercise, social bonding, and emotional well-being, as well as
amelioration of psychiatric problems such a autism and depression. ”
“It is proposed that LDN can be used effectively as a buffer for a large variety of bodily and mental ailments…”
“We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells.”
“Our findings that baseline ESR may be associated with LDN response suggest that other inflammatory conditions, such as rheumatoid arthritis, polymyalgia rheumatica, and lupus, may benefit from LDN.”
“A significant reduction of spasticity was measured at the end of the trial.”
“Our data clearly indicate that LDN is safe and well tolerated in patients with PPMS.”
Revisiting the ALA/N (a-Lipoic Acid/Low- Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases
[Patient #1] GB was declared to be in radiological remission by PET surveillance… At the time of this writing, 39 months after her diagnosis, GB continues with her treatment plan and has no signs of pancreatic disease.[Patient #2] “…6 months following the initiation of therapy, her PET scan failed to demonstrate disease recurrence.”[Patient #3] “…another PET scan was performed. It showed a resolution of the previously demonstrated pancreatic and retroperitoneal lesions.”
“…the integrative therapy described in this article may have the possibility of extending the life of a patient who is customarily considered terminal.”
WHO CANNOT TAKE LDN?
If you have had an organ transplant and are taking immune-suppressing therapy, you cannot take LDN.
Taking LDN can potentially lead to organ rejection.
If you are taking long-acting or continuously-administered “opiate” pain medicine, you cannot take LDN.
Taking LDN will likely lead to an immediate opiate withdrawal reaction (pain, nausea, vomiting, diarrhea, sweating).
Examples of opiates include codeine, oxycodone, morphine, fetanyl, methadone, hydromorphone, tramadol.
WHO CAN TAKE LDN?
Almost everyone else! Check with your naturopathic doctor or medical doctor to confirm LDN is right for you.
PURCHASE LDN CAPSULES OR NATURALLY FLAVOURED ORAL LIQUID
ONLINE PURCHASE OF PRESCRIPTION MEDICATION COMING IN MAY 2017! (FOR MEDICOR PATIENTS ONLY)
IF YOU ARE NOT A PATIENT YET, PLEASE CONTACT THE MEDICOR OFFICE TO ARRANGE A MEDICAL CONSULTATION PRIOR TO PURCHASE